大行評級丨美銀:上調阿里健康目標價至5.5港元 平台業務動能改善且盈利能力擴張
美銀髮表報吿,維持對阿里健康“買入”評級,目標價從5.2港元上調至5.5港元,認為公司平台業務動能改善且盈利能力擴張。該行認為阿里健康股價上行催化劑包括在線渠道的社會醫療保險支付,以及受惠於淘寶流量增長和購物場景擴展。該行指,阿里健康2025財年收入按年升13%略勝預期,主要受下半財年直銷業務增長加速推動。非公認會計准則淨利潤符合市場預期,但低於該行預期,原因是銷售與市場推廣支出較高。公司管理層預計現財年收入增長5%至10%,對比市場預期增10%;非公認會計准則淨利潤料按年升10%至20%,對比市場預期增25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.